Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E |
| Therapy | RG6344 |
| Indication/Tumor Type | melanoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E | melanoma | predicted - sensitive | RG6344 | Case Reports/Case Series | Actionable | In a Phase I trial, RG6344 treatment was well tolerated and demonstrated preliminary activity in patients with advanced solid tumors harboring BRAF V600E (n=64), including melanoma (n=11) and colorectal cancer (n=51), with an objective response rate of 25% (Cancer Res (2025) 85 (8_Supplement_2): CT017). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Abstract CT017: A phase I study evaluating safety, pharmacokinetics, and clinical activity of the novel, paradox breaker BRAF inhibitor RG6344 in patients with BRAF V600-mutant solid tumors | Full reference... |